- 2019 - 2022 Molecular mechanism of platelet integrin activation and association with vascular lesion
- 2018 - 2021 Analysis of regulatory mechanism for platelet integrin activation kinetics
- 2018 - 2021 Characteriziation of regulatory molecules of platelet integrin function and their clinical application
- 2016 - 2019 Analysis of platelet integrin signaling and association with vascular diseases
- 2015 - 2018 Elucidation of the role of kindlin in the functional expression of beta3 integrins and investigation of the kindlin-related new molecules
- 2015 - 2018 Identification and characterization of integrin inside-out signaling molecules employing a newly developed expeimental system
- 2014 - 2017 Analysis of regulatory mechanism of sustained integrin alphaIIbbeta3 activation.
- 2013 - 2016 Arterial thrombosis and platelet integrin activation.
- 2014 - 2015 インテグリンを制御する細胞骨格蛋白ネットワークの解明と造血器腫瘍治療への応用
- 2012 - 2015 Analysis of regulatory molecule in platelets for thrombosis employing CMK cell system
- 2011 - 2015 Elucidation of the role of ILK in the functional expression of beta3 integrins and investigation of the ILK-related molecules
- 2011 - 2013 Development of new therapy based on a molecular mechanism of integrin activation signaling via integrin activation complex
- 2009 - 2011 Analysis of positive or negative regulatory mechanism for thrombus formation
- 2008 - 2010 Cloning and analysis of molecules involved in functional regulation of β3 integrin
- 2008 - 2010 Development of new therapy based on a molecular mechanism of integrin activation signaling via integrin binding proteins
- 2008 - 2010 Analysis of inhibitory mechanism and antithrombotic effects of a novel anti-platelet function molecule, semaphorin 3A
- 2007 - 2008 Analysis of regulatory mechanism for α_<IIb>β_3 function by employing newly developed experimental system.
- 2006 - 2007 Analysis of anti-platelet and anti-thrombotic effects of a neuron guidance molecule,semaphorin 3A
- 2006 - 2007 Identification of signaling molecules associated with β3 integrins using random mutagenesis
- 2006 - 2007 Development of new targeted therapy ford thrombosis or cancer based on a molecudar mechanism of iniegrin activation signaling.
- 2006 - 2007 アディポネクチンの作用機序解明:新しい受容体の同定と結合蛋白の網羅的解析
- 2005 - 2006 Establishment of a novel IFN therapy with little side effects
- 2004 - 2004 新規インターフェロンLimitinを中心としたがん治療戦略の確立
- 2003 - 2004 Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
- 2003 - 2004 Characterization of regulatory proteins for β3 integrins.
- 2002 - 2003 Analyses of inhibitory effects induced by the loss-of-function mutant integrin cellular functions
- 2002 - 2002 新種のインターフェロンlimitin:新しい癌治療薬としての流動的検討
- 2001 - 2002 Biological activity of limitin and adiponectin
- 2001 - 2002 CD36 AS A GENETIC BACKGROUND FOR METABOLIC SYNDROME AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
- 2001 - 2002 Clinical application of limitin that has anti-tumor and anti-viral activity
- 2001 - 2001 骨髄抑制の少ない新規インターフェロン様蛋白limitinの癌治療への応用
- 2001 - 2001 新規造血制御分子limitin,adiponectinの生体内役割の解析
- 2000 - 2001 Development of Oxidized LDL Receptor (CD36) Knockout Mice and Its Application to Elucidation of Molecular Mechanism for Atherogenesis
- 2000 - 2001 Structural and functional analyzes of integrin αvβ3 : identification of ligand-binding sites in the αv subunit of αvβ3 and development of inhibitor for αvβ3
- 2000 - 2001 Regulatory mechanism of β3 integrin function via signaling molecules
- 2000 - 2000 機能変異インテグリン導入によるがん細胞遊走能および転移能の解析
- 1999 - 2000 Establishment of A New Strategy for the Treatment of Atherosclerosis by Inhibition of an Oxidized LDL Receptor, CD36
- 1999 - 1999 新規に固定した造血制御分子の作用機序およびその生体内意義
- 1999 - 1999 ストローマ細胞由来造血制御分子の同定とその生体内意義
- 1998 - 1999 Pathophysiological Analysis of CD36 Deficiency As a Novel Cause of Idiopathic Cardiomyopathy; Role of Long-chain Fatty Acid Transporter, CD36, in Myocardial Energy Metabolism
- 1998 - 1999 Mechanisms of autoantibody-mediated pathological thrombosis in the mouse model with antiphospholipid symdrome
- 1998 - 1998 造血幹細胞支持に関わるストローマ細胞由来分子の同定-造血幹細胞への結合能を指標とした新しいクローニング法を用いて-
- 1997 - 1998 Signaling through integrin alpha IIb beta3
- 1997 - 1998 Gene targeting of CD36, the major receptor for oxidized low density lipoproteins
- 1996 - 1996 トロンボポエチン産生調節機構の解析
- 1996 - 1996 リコンビナント蛋白を用いた血小板インテグリンαIIbβ3の機能発現機構の解析
- 1996 - 1996 酸化LDL受容体阻害による新しい粥状動脈硬化治療法の開発
- 1995 - 1995 酸化LDL受容体CD36の構造と機能に関する研究-CD36欠損細胞および分子生物学的手技を用いた検討-
- 1995 - 1995 血小板インテグリンαIIbβ_3の活性化機構に関する研究
- 1994 - 1994 血小板インテグリンαIIbβ_3の構造と機能に関する分子生物学的解析
- 1994 - 1994 Oxidized LDL受容体としてのCD36(GPIV)に関する分子生物学的研究
- 1993 - 1993 ヒト白血病細胞における増殖シグナル伝達分子の活性化とその制御機構に関する研究
- 血栓・止血の分子機構、血小板異常症の分子病態
- 特発性血小板減少性紫斑病における血小板抗体
- 血小板無力症の遺伝子解析
- 血小板インテグリンαIIbβ3の構造機能連関
- Study on anti-platelet autoantibodies in chronic ITP
- Molecular genetic basis of Glanzmann's thrombasthenia
- Structure-function relationship in integrin αIIbβ3
Show all